fashion -WSS

fashion

author：focus 2025-09-11 10:30:21 - browse：48364

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown. — Metastatic melanoma cells Julio C. Valencia,/NCI Center for Cancer Research

Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.

“It’s so exciting and gratifying,” said Allison Betof Warner, a cell therapy researcher and physician at Stanford University who has worked on Amtagvi. “This is a game-changing moment for our field. We’ve seen huge success of cellular therapy for hematologic malignancies, and we’ve yet to capitalize on that for solid tumors. This is hopefully the first of many to come.”

In a Phase 2 clinical trial, titled C-144-01, 153 patients who had already been on a median of three prior lines of therapy received lifileucel, and 31% of them responded to therapy. “These are in very late line patients. They’ve exhausted every standard care option,” Betof Warner said. “The most promising part of this therapy for me is that 42% of patients who responded were still responding for 18 months or longer. It’s truly incredible.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： AI gets buy

focus

WSS

AI gets buy

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Medical student insurance fails on mental health care coverage

It's been 20 years since Dolly the sheep. Where's my clone?

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

What’s missing from the debate over nursing home staff minimums

hotspot

fashion

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

EpiPen alternative approval delay highlights citizen petition issue

Walensky prepares to leave CDC — and Congress — behind

Thermo Fisher plant for manufacturing gene therapies to expand

Guidelines to prevent youth baseball injuries need more muscle

Problems with a popular proposal to regulate AI in health care

Heart attack and stroke risk calculators need revising

Why Novartis is going to walk from its acquisition of MorphoSys

Duchenne breakthrough therapy leaves behind pioneering families

Biotech stock slump in 2023: awaiting the turnaround

entertainment

Second xenotransplant done with gene

Unique patient identifier: Experts argue the benefits, pitfalls

FDA panel to weigh approval of NurOwn, controversial ALS drug

STAT Virtual Event: Putting AI to the Test

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Global cancer cases to surge 77% by 2050, WHO report says

focus

hotspot

explore

Wikipedia